News

Voyager Therapeutics will soon initiate a global Phase 2/3 clinical trial program to evaluate its VY-AADC gene therapy for the treatment of advanced Parkinson’s disease. The trial follows approval by the U.S. Food and Drug Administration of the company’s investigational new drug (IND) application…

Repetitive transcranial magnetic stimulation (TMS) does not appear to treat depressive symptoms in patients with Parkinson’s disease, although it may improve motor symptoms, an analysis of nine clinical trials found. But the study included relatively few patients, so the researchers, with Guangxi University of Science and Technology in China, said that their conclusions warrant further exploration…

A new technology that reduces “shaky hands” in people with essential tremor (ET) may benefit those with Parkinson’s disease. People with essential tremor, a condition that has overlapping motor features with Parkinson’s disease, have a significant reduction in their quality of life, as everyday tasks such as drinking from a…

The Parkinson’s Foundation has enrolled the 10,000th patient in the largest clinical trial of the disease yet to be conducted. Among the critical discoveries so far, the research has shown that regular visits to neurologists, more exercise, and more attention to mental health could help improve patients’ wellbeing. The…

Defects in mitochondria, the cell’s microscopic powerhouses, might actually protect Parkinson’s disease patients, a Norwegian study suggests. The findings show that, contrary to all current theories, deficiencies in complex I — a key component of mitochondria — exist randomly throughout the brains of Parkinson’s patients, not only in affected regions. In…

Levodopa improves Parkinson’s patients’ symptoms by binding with two types of receptors for dopamine, a neurotransmitter that helps regulate movement and emotional response. Although it is considered the gold standard in Parkinson’s treatment, a study from Binghamton University students contends that levodopa’s interaction with the dopamine receptor D2 may cause involuntary…

Mutations in the LRRK2 gene, a major genetic factor contributing to Parkinson’s disease, may likely affect the risk for Crohn’s disease, an inflammatory bowel disease, researchers at Mount Sinai in New York discovered. The results suggest a potential genetic link between Crohn’s disease and Parkinson’s and common disease…

An Axovant Sciences therapy for Parkinson’s disease showed signs of effectiveness, but an Alzheimer’s treatment did not, according to separate Phase 2 clinical trials. Nelotanserin, the therapy candidate for Parkinson’s disease dementia (PDD) associated with hallucinations and for Dementia with Lewy Bodies (DLB), appeared safe as well as displaying signs of effectiveness,…

It’s widely accepted that Parkinson’s disease (PD) patients experience neuronal death in the brainstem. Now, for the first time, researchers report that the number of copies of mitochondrial DNA is increased in the surviving nerve cells within this area of the brain. Interestingly, specific brainstem neurons had more alterations in…

Adamas Pharmaceuticals is making a concerted effort to spread the word on its flagship treatment for the involuntary muscle movements that are a hallmark of Parkinson’s disease. The U.S. Food and Drug Administration approved Gocovri (amantadine) in August 17. Adamas began making the extended release capsules available in the United States in…